Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Marius Ardeleanu, Andrew Blauvelt et al.|The Lancet|2015Cited by 566
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)Kristian Reich, Howard Sofen, Craig L. Leonardi et al.|Journal of Dermatological Treatment|2016Cited by 56